Abstract: An infant incubator heat control device includes a temperature-detecting device providing chamber interior and incubator heater temperature measured values. A first mode of operation has an interior temperature set value, a temperature of the heater set value is calculated as a function of the interior temperature set value and of the chamber interior temperature measured value. A controlled variable is calculated for the heater as a function of the temperature of the heater set value and of the heater measured value. A second mode of operation calculates a temperature of the heater set value independently of the chamber interior temperature measured value. A controlled variable is calculated for the heater as a function of the set value for the temperature of the heater and of the heater temperature measured value.

Abstract: An incubator comprises an incubator chamber defined by a bottom part and a top casing covering a bed area of the bottom part. The incubator comprises an air treatment and circulation device for treating air and circulating it through the chamber, said air treatment and circulation device including a ventilator. The air treatment and circulation device is connected to chamber inlet openings which are arranged along one or more sides of said bed area, allowing treated air to flow from the treatment and circulation device into the chamber. The air treatment and circulation device furthermore is connected to at least one chamber outlet opening allowing air to flow out from the chamber to the treatment and circulation device. The air flows in the incubator are routed such that noise is reduced and no high air flow speeds occur near the infant in the incubator.

Abstract: Systems and processes of controlling a function of a person support apparatus are provided. An example system includes a person support apparatus adapted to support a patient. The person support apparatus comprising a controller adapted to communicatively couple with at least one removable component of the person support apparatus. The controller is adapted to determine the absence or presence of the at least one removable component. In response to the determination, the controller is further adapted to disable at least one movement of the person support apparatus in response to a determination that the at least one removable component is not present or enable the at least one movement in response to a determination that the at least one removable component is present.

Abstract: A device for enhancing grip strength and forearm health of a user is disclosed herein. The device comprises a body in the form of a strap, a cuff disposed within a portion of the body, a tensioner comprising a rounded contact point and a threaded bolt. The device of the present invention allows a user to stretch and expand the fascia, allowing for blood to be increased in these muscles with less restriction.

Abstract: A crutch air cushion device, including an inflatable housing that slides on top of a crutch, where the inflatable housing includes an upper chamber and at least one side chamber, and a valve for air inlet and outlet. The device further includes an upper chamber has an outer surface on the outside of the inflatable housing and an inner surface on the inside of the inflatable housing, and the valve positioned on the inner surface of the upper chamber. A crutch air cushion device, including an inflatable housing with a plurality of air chambers, and a valve positioned on the inner surface of the inflatable housing that contact the upper surface of a crutch. A method of pressurizing a crutch air cushion device, including sliding an inflatable housing on a crutch, inserting air into the inflatable housing through a valve located on an inner surface of the inflatable housing, and filling an upper chamber and at least one side chamber of the inflatable housing with the air.

Abstract: A Unified Dildo and Bottom Open Anatomically Contoured Harness Plate that includes a harness plate with an outer surface and an inner surface, wherein the harness plate is contoured, at least one elongated member with a base and a tip, the base extending outward from the outer surface of the harness plate; the elongated member includes cavity enclosed by the outer surface and opens to the inner surface; an opening in the inner surface and outer surface of the harness plate, positioned underneath the base of the elongated member; and at least one upper connection mount and at least one bottom connection mount on the harness plate for securing the harness plate to a user.

Abstract: A percussive massage device includes an enclosure having a cylindrical bore that extends along a longitudinal axis. A motor has a rotatable shaft that rotates about a central axis perpendicular to the longitudinal axis. A crank coupled to the shaft includes a pivot, which is offset from the central axis of the shaft. A reciprocation linkage has a first end coupled to the pivot of the crank. A piston has a first end coupled to a second end of the reciprocation linkage. The piston is constrained to move within a cylinder along the longitudinal axis of the cylindrical bore. An applicator head has a first end coupled to a second end of the piston and has a second end exposed outside the cylindrical bore for application to a person receiving treatment. A motor controller measures current applied to the motor and displays a pressure indicator responsive to the measured current.

Abstract: Disclosed herein is an improved eyelid care appliance and method of using such appliance for preventing and treating blepharitis and mammalian meibomian gland dysfunction caused by gland obstruction. The method and apparatus of the invention enable restoration and maintenance of eyelid hygiene and the natural flow of secretions from the meibomian glands. A preferred embodiment of the apparatus comprises an oscillating spongehead affixed to the distal end of the eyelid care appliance that is equipped with a video camera, near field communications link, and a display, thereby enabling a user to “fly” the spongehead onto an eyelid margin for self-administered cleaning of the user's eyelid margins. The spongehead can be impregnated with topical pharmacologic or cleansing agents to better facilitate cleaning and therapeutic efficacy.

Abstract: Fluid transfer systems are disclosed that can be configured to transfer precise amounts of fluid from a source container to a target container. The fluid transfer system can have multiple fluid transfer stations for transferring fluids into multiple target containers or for combining different types of fluids into a single target container to form a mixture. The fluid transfer system can include a pump and a destination sensor, such as a weight sensor. The fluid transfer system can be configured to flush remaining fluid out of a connector to reduce waste, using air or a flushing fluid.

Abstract: Some embodiments disclosed herein related to a device for transferring precise amounts of fluid from at least one source container to at least one target container. In some embodiments, the fluid is first transferred from the source container (e.g., a vial) through a connector to an intermediate measuring container (e.g., a syringe). In some embodiments air can pass through an air inlet and enter the vial to compensate for the volume of fluid withdrawn from the vial. An air check valve or a bag or a filter can prevent the fluid from escaping through the air inlet. The precisely measured amount of fluid can then be transferred from the intermediate measuring container to the target container (e.g., an IV bag). In some embodiments the connector can include a source check valve and a target check valve to direct fluid first from the source container to the intermediate measuring container and then from the intermediate measuring container to the target container.

Abstract: A medicament dispensing container includes a first wall connected with a second wall and defines a cavity therebetween. The walls are movable between an open configuration and a closed configuration. At least one member is disposable in the cavity and defines at least one dose receptacle configured for disposal of at least one dose of at least one medication. At least one fixation member connects the at least one member to at least one of the walls such that the at least one member is movable relative to the wall. Systems and methods of use are disclosed.

Abstract: There are provided a dispensing inspection device, a dispensing inspection method, a program, and a recording medium capable of inspecting whether dispensing is appropriately performed with high reliability. By obtaining a first image captured by imaging a rear surface of a medicine sheet and a second image obtained by imaging a lateral side thereof, and a third image obtained by irradiating a front surface of a fractional medicine with light from an inclined lower side, detecting a medicine name using OCR and/or code recognition from the first image, detecting the number of medicine sheets from the second image, detecting the number of fractional medicines from the third image, detecting a total number of medicines from the number of the medicine sheets and the number of the fractional medicines, and determining whether a medicine name and the number of medicines in prescription information and the detected medicine name and the detected total number of medicines match each other.

Abstract: A device for storage and supply of at least one oral requirement-fulfilling element for an infant and/or a toddler includes a storage unit for storing the oral requirement-fulfilling element, a filling unit for filling the storage unit with the at least one oral requirement-fulfilling element, and an output unit for retrieving the at least one oral requirement-fulfilling element from the storage unit. A conveying apparatus conveys the at least one oral requirement-fulfilling element from the filling unit to the output unit.

Abstract: The present invention provides organic-inorganic composite particles having a suitable biodegradability. The organic-inorganic composite particles of the present invention include a silica component and a biodegradable plastic. The organic-inorganic composite particles have a mean particle diameter (d1) ranging from 0.5 ?m to 25 ?m, an absolute specific gravity greater than 1.0 g/cm3 and equal to or smaller than 2.0 g/cm3, and a contact angle with water of 90° or less. A cosmetic product including the organic-inorganic composite particles has good texture characteristics.

Abstract: Disclosed is a water-in-silicone emulsion and methods for its use that includes 5% to 8% w/w of octinoxate, 1% to 3% w/w of niacinamide, 0.01% to 0.1% w/w of Salix nigra bark extract, 0.01% to 0.1% w/w of adenosine, and 0.001% to 0.01% w/w of Silybum marianum extract.

Abstract: An oral composition is provided comprising crosslinked polyvinylpyrrolidone (PVP) and xylitol. The xylitol and the crosslinked PVP are in a ratio of about 5:1, and the oral composition is in the form of a lozenge or lollipop. Methods are also provided.

Abstract: The present disclosure relates to new UV-filters, method of producing the same and their use in compositions in particular, cosmetic/pharmaceutical or textile compositions, namely sunscreens cream or sunscreens textile article, in particular the present disclosure relates to hydroxyapatite based-compound comprising Ca9FeH(PO4)7 and/or ?-Fe2O3 in hematite form for use in a method for protecting the skin against UV radiation.

Abstract: The present invention relates to a composition for dyeing keratin fibers, in particular keratin fibers such as the hair, comprising: a) at least one oxidation base 3-(2,5-diaminophenyl)-1-propanol and/or acid salts thereof or solvates thereof such as hydrates; b) at least one coupler; c) at least 10% by weight of the total weight of the composition of a fatty substance which is preferably liquid and non-silicone-based; d) at least one nonionic surfactant chosen from alkyl(poly)glycoside surfactants, esters of oxyalkylenated sorbitan and fatty acids and oxyalkylenated fatty alcohols; e) optionally at least one basifying agent; and f) optionally at least one chemical oxidizing agent. The invention also relates to a process for dyeing keratin fibers such as the hair using the composition of the invention, and to a multi-compartment device for using the composition of the invention.

Abstract: Sun-care products are described that protect from UV radiation and do not turn white when applied to wet skin. The sun-care product may comprise (A) a cosmetically-acceptable, substantially non-aqueous vehicle, and (B) a UV active, wherein said non-aqueous vehicle comprises alcohol in an amount of 50% (w/w) or less based on the weight of the sun-care product and an ester wherein said non-aqueous vehicle comprises at least 10%>by weight esters based on the total weight of the non-aqueous vehicle and said sun-care product is substantially non-whitening upon application to wet skin.

Abstract: In one aspect, a method of increasing hair growth includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor. In another aspect, a method of improving the appearance of hair includes administering to an individual in need thereof a pharmaceutical composition containing a therapeutically effective amount of isomyosmine or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable vehicle therefor.

Abstract: The present invention relates to the field of dental care, in particular, to a dental care product such as toothpaste (dentifrice), prophylactic paste, tooth powder, tooth polish, tooth gel, chewing gum, candy, lozenge, mouthwash, whitening strip, coated dental floss, coated toothbrush, paint-on gel, varnish, veneer, and tube, syringe or dental tray comprising a gel or paste, mouthwash, whitening strips and trays for whitening teeth, wherein the product comprises mineral particles such as crystals and a compound, preferably, a protein capable of forming a matrix which is a hydrogel, wherein the product comprises a fluorophore. The mineral particles may comprise, e.g., calcium phosphate, preferably, hydroxyapatite, preferably, in crystalline form. The protein matrix may comprise, e.g., a self-assembling peptide. The product also comprises a fluorophore, which may be a fluorescent amino acid residue of the protein matrix.

Abstract: A composition for delivery of a hydrophobic bioactive agent is provided that provides for a partially solubilized storage solution that upon exposure to the air results in a fully solubilized bioactive agent in a molecular form for optimal delivery to the skin of a subject. The composition is used for the therapeutic treatment or diagnosis of numerous skin conditions such as inflammation, and epidermal or musculoskeletal pain.

Abstract: The present invention relates to an anhydrous composition comprising: 1) at least particles comprising a core containing at least one beneficial agent and an envelope surrounding the core; said envelope comprising at least one hydrophobically modified polysaccharide and at least one water-soluble carbohydrate and/or water-soluble polyol; said particles simultaneously having a poured powder density ranging from 300.0 g/l to 600.0 g/l and an absolute density of greater than 1.0; and 2) an oily phase. The invention additionally relates to a cosmetic process for caring for and/or for making up a keratin material, which consists in applying to the surface of said human keratin material a consumer product comprising a composition as defined previously.

Abstract: A transdermal formulation which can be applied to the skin as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, glycol, sodium bicarbonate and base cream resilient in the presence of a wide range of drugs while increasing permeation of active antioxidant agents, water, isopropyl myristate, polyoxyethylene sorbitan monooleate, isopropyl palmitate, ascorbic acid, and dimethyl sulfoxide. The dosage amount can create in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

Abstract: The invention refers to a drippable ophthalmic gel, said gel having composition comprising bimatoprost in an amount of 0.003 to 0.03% by weight, polyacrylate in an amount of >0.2% by weight, povidone (PVP), dextrane, polyethylene glycols (PEG), carboxymethyl cellulose (CMC) or poly(vinyl alcohol) (PVA) in an amount of 0.2 to 10% by weight, an isotonizing agent in an amount to produce an osmolality of 200 to 400 mosml/kg, a salt for adjusting the viscosity in an amount of 0.05 to 0.4% by weight, a base in an amount to adjust the pH to 6 to 8 and excipients normally used in ophthalmic gels, having a viscosity in the range of 200 to 2000 mPa·s.

Abstract: A control unit for controlling the operation of a nebulizer is provided that is configured to measure the impedance of an actuator in the nebulizer and to determine whether a nebulizing element in the nebulizer is positioned correctly with respect to the actuator on the basis of the measured impedance. Also provided is a nebulizer comprising a reservoir chamber for storing a liquid to be nebulized, an actuator for vibrating liquid stored in the reservoir chamber, and a control unit as described above.

Abstract: A pharmaceutical solution with a pH value of 10 or higher contains an angiotensin II receptor antagonist, where one or more sugar alcohols are present up to a total concentration of 40 wt. % to 70 wt. %.

Abstract: The present invention relates to articles and methods of treating vascular conditions with a thixotropic, turbid, bioactive agent-containing gel material capable of being essentially removed from an implantation site upon re-establishment of fluid flow at the implantation site.

Abstract: A process for preparing dry powder formulations of a glycopyrronium salt for inhalation that have good stability. The process involves (a) micronising a glycopyrronium salt together with an anti-adherent agent, and (b) admixing carrier particles to form the dry powder formulation.

Abstract: The present invention provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time. The methods and compositions according to the invention are useful as therapeutic tools to prevent, reverse, and/or reduce the symptoms of allergic and/or inflammatory conditions in a mammalian patient. The invention also provides methods and compositions, which may be manipulated and fine-tuned to fit the condition(s) to be treated while producing fewer side effects.

Abstract: Provided is a hydroxyalkyl alkyl cellulose exhibiting good flowability and high compressibility. More specifically, there are provided a hydroxyalkyl alkyl cellulose having a volume-based average particle size, determined by dry laser diffractometry, of more than 100 ?m and not more than 150 ?m; and after dividing all particles into fine particles, spherical particles and fibrous particles by a dynamic image analysis, a volume fraction of the fibrous particles relative to all of the particles of more than 40% and not more than 50%, and a volume fraction of the fine particles relative to all of the particles of less than 2.0%; a solid preparation including the hydroxyalkyl alkyl cellulose; and others.

Abstract: A controlled release delivery device for controlled release of an active ingredient comprising: (i) a core particle comprising the active ingredient homogenously dispersed or dissolved therein; and (ii) an organosol polymeric coat comprising a homogenous mixture of, (a) a water soluble gel forming polymer and a water insoluble organosoluble polymer in a dry weight ratio of from about 20:80 to about 50:50, (b) an organosolvent, and (c) an anti-tacking agent; the organosol polymeric coat being applied directly to and substantially enveloping the core particle.

Abstract: An oral pharmaceutical composition comprising a drug and one or more pharmaceutically acceptable excipients in a monolithic dosage form, wherein the dosage form is configured such that when the dosage form is divided into more than one piece and at least one of the pieces is administered to a subject the Cmax, AUC, and/or rate of drug released after administration is substantially the same or lower and the Tmax is higher than the Cmax, AUC, rate of drug released, and/or Tmax after administration of: (1) a comparable composition in intact dosage form of equal drug dosage of the administered at least one piece; (2) a bioequivalent drug composition in an intact dosage form of equal drug dosage to the administered at least one piece; and (3) a divided piece of a bioequivalent drug composition, wherein the divided piece comprises a drug dosage equal to the dosage of the administered piece of the oral composition. Methods of making the same and methods of using the same are also provided.

Abstract: Shelf life of soft gelatin capsules comprising a soft gelatin shell encapsulating a pharmaceutical formulation comprising cis-5,8,11,14,17-eicosapentaenoic acid (C20:5 n-3; “EPA”) in free acid form in an amount from 25 wt % to 99 wt % of the formulation and cis-7,10,13,16,19-docosapentaenoic acid (C22:5 n-3; “DPA”) in free acid form in an amount from 1 wt % to 75 wt % of the formulation in which the gelatin component of the shell is Type B gelatin, is improved by replacing up to 75 wt % of the gelatin component with porcine Type A gelatin.

Abstract: Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.

Abstract: The invention provides an adhesive sheet for skin, which shows sufficient adhesiveness to the skin and causes low skin irritation. The adhesive sheet contains an adhesive layer formed on a support, in which the adhesive layer contains at least a thermoplastic elastomer, a non-volatile hydrocarbon oil, and polyisobutylene, but no tackifier. The polyisobutylene is a medium molecular weight polyisobutylene with a viscosity average molecular weight of more than 100,000 and not more than 500,000. The invention also provides a percutaneous absorption preparation containing a drug or a pharmaceutically acceptable salt thereof in an adhesive layer of the inventive adhesive sheet for skin.

Abstract: The present technology relates to a method of treating one or more behavioral symptoms of Autism Spectrum Disorder (ASD) in a subject by transdermally administering an effective amount of cannabidiol (CBD) to the subject wherein one or more behavioral symptoms of ASD are treated in the subject.

Abstract: The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.

Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.

Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.

Abstract: Disclosed herein are ?-galactosylceramide (?-GalCer) analogs and compositions thereof, methods of activating invariant Natural Killer T (iNKT) cells using said analogs, methods of treating diseases by activating iNKT cells using said analogs, and combination therapy of said analogs.

Abstract: This invention is directed to pyrrole, pyrazole, imidazole, triazole, and morpholine based selective androgen receptor degrader (SARD) compounds including heterocyclic anilide rings and their synthetic precursors, R-isomers, and non-hydroxylated and/or non-chiral propanamides, and pharmaceutical compositions and uses thereof in treating prostate cancer, advanced prostate cancer, castration resistant prostate cancer, triple negative breast cancer, other cancers expressing the androgen receptor, androgenic alopecia or other hyperandrogenic dermal diseases, Kennedy's disease, amyotrophic lateral sclerosis (ALS), abdominal aortic aneurysm (AAA), and uterine fibroids, and to methods for reducing the levels of androgen receptor-full length (AR-FL) including pathogenic or resistance mutations, AR-splice variants (AR-SV), and pathogenic polyglutamine (polyQ) polymorphisms of AR in a subject.

Abstract: The present invention is directed to tablets for oral administration to a subject, comprising a therapeutically effective amount of SYN120 or a pharmaceutically acceptable salt thereof, wherein the tablet is substantially free of lactose. The present invention is also directed to methods for treating diseases or conditions including Alzheimer's disease and/or Parkinson's disease, comprising administering to a patient in need thereof tablets regarding the same.

Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.

Abstract: The present invention generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present invention comprises a composition comprising pyruvic acid and/or a pyruvate salt. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments, the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present invention are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: The invention provides coated particles with a taste-masked drug substance. The particles comprise a core with the agglomerated active ingredient and a coating comprising a triglyceride and a surfactant. The particles exhibit rapid drug release and a stable release profile. Moreover, the invention provides a hot-melt coating method for manufacturing such particles, and pharmaceutical compositions comprising the particles. The method allows the coating of core particles at moderate temperatures, thereby preventing the degradation of the thermolabile active ingredient.

Abstract: Among other things, the present invention provides novel isoprenyl compounds capable of effectively modulating inflammatory responses and pharmaceutical, cosmetic, cosmeceutical and topical compositions comprising these isoprenyl compounds. Anti-inflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with inflammation. Proinflammatory compounds of the present invention are useful in treating or preventing diseases or conditions associated with suppression of inflammatory responses. Thus, the present invention also provides methods useful in the treatment or prevention of diseases or conditions associated with inflammation as well as methods useful in the treatment or prevention of diseases or conditions associated with suppression of inflammatory responses.

Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising eicosapentaenoic acid and/or derivatives thereof and nicotinic acid, to methods of manufacturing such compositions, and to therapeutic methods for treating carious diseases and disorders.

Abstract: A method of photoprotecting cells of the retinal pigment epithelium (EPR) in mammals using a composition having norbixin. The norbixin is produced by purification from an extract of Bixa orellana seeds.

Abstract: The present invention relates to methods of preventing a psychotic disorder in a subject in need of intervention including administering to the subject a composition including EPA (eicosapentanoic acid) and DHA (docosahexaenoic acid). Methods of treating pre-psychotic symptoms in a subject, including administering to the subject a composition including EPA and DHA are also included.